Adamax
What do these badges mean?
Evidence tier
- AHuman-validated — Human trials showing positive results and good safety.
- BAnimal-grade — No human trials yet, but solid animal/preclinical evidence of effect and safety.
- CAnecdotal — No human or animal trials — only anecdotal/observational reports.
- DInsufficient evidence — No or insufficient evidence (encyclopedia only — never recommended by the builder).
Safety light
- 🟢 Green — Only mild, manageable side effects; reasonable safety data.
- 🟡 Yellow — Needs active management, has a meaningful contraindication/interaction, or has thin long-term data.
- 🔴 Red — Risk of a hospital-level event — treat with serious caution.
Browse-only — not on the protocol builder's curated shortlist, so the builder won't recommend it.
What is it?
Adamax is a synthetic nootropic peptide, described as a modified/enhanced variant in the Semax lineage: derived from a fragment of ACTH (adrenocorticotropic hormone). It’s identified specifically as an ACTH(4-10) fragment derivative. Semax itself is the better-evidenced relative — see Semax for the human (Russian-school) data behind that mechanism family.
What does it do in my body?
As a modified ACTH fragment, Adamax is claimed to influence neurotransmitter activity and BDNF levels, the same melanocortin-system / neurotrophic mechanism that underpins Semax’s nootropic reputation. The pitch is “Semax, but enhanced.”
How can it help me?
- Where the science stands: None captured; 0 studies cited, 0 human trials
The full evidence — every human, animal, and lab study, graded — is one tap away: use the See the deeper science → toggle at the top.
Is it dangerous? What are the side effects?
Not documented. No human trials exist for Adamax specifically in the record this KB draws from.
Regulatory status: Research compound — not approved for human use. Tier D / encyclopedia-only. If a reader wants the evidenced version of this mechanism, Semax is the one with the human data behind it.
Typical dosing
Educational context only — talk to a licensed medical provider before any protocol. What follows describes the doses and schedules most commonly reported in the research and by practitioners, shared so you can have an informed conversation. These compounds are sold for research use only, are not FDA-approved drugs, and this is not medical advice.
None exists in the source material, and none should be inferred from Semax’s protocol — Adamax has not been shown to behave identically to Semax in any captured study. Treat this as a compound with a plausible mechanistic story and no dosing evidence of its own.
What should I avoid combining — and what's synergistic?
Adamax doesn't have a dedicated stacking protocol in our notes — the interactions that matter most are in the safety section above. For how people combine it with other peptides, the deeper-science view has the full detail.
Where do people source this?
OHM does not sell or handle any compound. Research-use-only material is sold by third-party vendors; our vetting notes and disclosures are on the Where to buy page. If you'd rather have a physician in the loop, see the telehealth option. Whatever the route, the supply chain is the real risk: only consider vendors that publish batch-level third-party Certificates of Analysis.
A modified ACTH-fragment peptide marketed as “Semax, but enhanced” — of the frontier compounds in this cluster, Adamax has the thinnest captured evidence of all, and even the foundational mechanism work it leans on belongs to a different, better-evidenced peptide.
| Class | Synthetic nootropic peptide, a modified/enhanced variant in the Semax lineage — an ACTH(4-10) fragment derivative |
| Mechanism (one line) | Claimed to influence neurotransmitter activity and BDNF levels via the melanocortin-system / neurotrophic mechanism underlying Semax |
| Evidence base | None captured; 0 studies cited, 0 human trials |
| Safety record | No human safety data captured |
| Regulatory status | Research compound; not approved for human use |
What it is
Adamax is a synthetic nootropic peptide, described as a modified/enhanced variant in the Semax lineage: derived from a fragment of ACTH (adrenocorticotropic hormone). It’s identified specifically as an ACTH(4-10) fragment derivative. Semax itself is the better-evidenced relative — see Semax for the human (Russian-school) data behind that mechanism family.
How it works
As a modified ACTH fragment, Adamax is claimed to influence neurotransmitter activity and BDNF levels, the same melanocortin-system / neurotrophic mechanism that underpins Semax’s nootropic reputation. The pitch is “Semax, but enhanced.”
What the research shows
The directory profile this article draws from lists 0 studies cited, 0 human trials, grades Adamax anecdotal, and states no published clinical studies were found on PubMed for Adamax specifically. The 0035 deep-research categorization pass grades it Tier D: minimal published data, encyclopedia-only. Of the frontier compounds in this cluster, Adamax has the thinnest captured evidence: even the foundational ACTH-fragment work it leans on belongs to Semax, not to Adamax specifically — there is no Adamax-specific study behind the claim, only inference from the parent compound’s mechanism.
Real-world protocol
None exists in the source material, and none should be inferred from Semax’s protocol — Adamax has not been shown to behave identically to Semax in any captured study. Treat this as a compound with a plausible mechanistic story and no dosing evidence of its own.
Side effects & management
Not documented. No human trials exist for Adamax specifically in the record this KB draws from.
Regulatory status
Research compound — not approved for human use. Tier D / encyclopedia-only. If a reader wants the evidenced version of this mechanism, Semax is the one with the human data behind it.
Sources
- (thepeptidelist.com directory capture, 2026-06-07)
- Tier D grading, ACTH(4-10) fragment derivative identification
- Migrated from
frontier-investigational-peptides-cluster.md(Section 1)
Sources & references
- (thepeptidelist.com directory capture, 2026-06-07)
- Tier D grading, ACTH(4-10) fragment derivative identification
- Migrated from
frontier-investigational-peptides-cluster.md(Section 1)